For example, results from Phase I and Phase II clinical trials with N. benthamiana-produced influenza vaccine showed that no subject developed an IgE response to xylose- or fucose-containing motifs, and no allergic/hypersensitivity response was detected in any subject, including subjects with pre-existing plant allergies [59,60]. The gene discussed is IGHE; the disease is influenza.